Novartis AG
NVSEF
$113.33
$3.653.33%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -19.59% | 124.64% | 111.49% | 116.98% | 113.52% |
| Total Depreciation and Amortization | 47.56% | -63.39% | -60.05% | -55.91% | -51.16% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 519.40% | -131.38% | -123.22% | -128.38% | -124.06% |
| Change in Net Operating Assets | 4.73% | -122.17% | -29.02% | -78.99% | -21.21% |
| Cash from Operations | 21.86% | -0.31% | -1.95% | -11.44% | 1.56% |
| Capital Expenditure | -28.87% | -26.46% | -25.43% | -35.31% | -15.72% |
| Sale of Property, Plant, and Equipment | -63.71% | 16.00% | 75.69% | 53.85% | 50.00% |
| Cash Acquisitions | -12.83% | -1.15% | -6,136.61% | -19,857.89% | -328.00% |
| Divestitures | 3,466.67% | -- | -1,166.67% | 4.35% | 137.50% |
| Other Investing Activities | -123.27% | -115.37% | -100.90% | -135.10% | 225.41% |
| Cash from Investing | -234.26% | -205.96% | -160.74% | -317.47% | 281.20% |
| Total Debt Issued | 411.84% | 4,403.55% | 2,540.61% | 129.35% | 513.10% |
| Total Debt Repaid | -1.09% | 6.54% | -65.69% | -23.18% | -22.66% |
| Issuance of Common Stock | -81.13% | -81.13% | -84.28% | -- | 59.00% |
| Repurchase of Common Stock | 4.50% | 32.73% | 50.21% | 36.91% | 18.10% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -5.09% | -5.09% | -5.09% | 28.23% | 3.34% |
| Other Financing Activities | -105.95% | -101.18% | 4,961.11% | 3,950.00% | 4,192.59% |
| Cash from Financing | 17.76% | 47.05% | 54.55% | 49.40% | 30.56% |
| Foreign Exchange rate Adjustments | -398.00% | 117.28% | -199.40% | -214.66% | 412.50% |
| Miscellaneous Cash Flow Adjustments | -- | 200.00% | -- | -- | -- |
| Net Change in Cash | -132.91% | -67.27% | -141.07% | -36.66% | 220.16% |
